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Abstract
Background: Recently, a new classification for gastric cancer (GC) has been proposed, based on Lauren’s histology and on
anatomic tumour location, identifying three subtypes of disease: type 1 (proximal non diffuse GC), type 2 (diffuse GC) and
type 3 (distal non diffuse GC). Aim of our analysis was to compare clinical outcome according to different GC subtypes
(1,2,3) in metastatic GC patients receiving first-line chemotherapy.
Patients and Methods: Advanced GC pts treated with a first-line combination chemotherapy were included in our analysis.
Pts were divided in three subgroups (type 1, type 2 and type 3) as previously defined.
Results: A total of 248 advanced GC pts were included: 45.2% belonged to type 2, 43.6% to type 3 and 11.2% to type 1.
Patients received a fluoropyrimidine-based chemotherapy doublet or three drugs regimens including a platinum derivate
and a fluoropyrimidine with the addition of an anthracycline, a taxane or mytomicin C. RR was higher in type 1 pts
(RR = 46.1%) and type 3 (34,3%) compared to type 2 (20,4%), (p = 0.015). Type 2 presented a shorter PFS, median PFS = 4.2
months, compared to type 1, mPFS = 7.2 months, and type 3, mPFS = 5.9 months (p = 0.011) and also a shorter OS
(p = 0.022).
Conclusions: Our analysis suggests that GC subtypes may be important predictors of benefit from chemotherapy in
advanced GC patients. Future clinical trials should take in account these differences for a better stratification of patients.
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Background
Despite its incidence in Europe and North America has declined
over the last three decades, gastric cancer (GC) is still the second
cause of cancer-related deaths worldwide [1], representing a
challenging problem for oncologists. Although different histolog-
ical subtypes of GC have been identified, in the daily clinical
practice and for the purpose of medical management, GC is
usually considered as a single disease.
The World Health Organization and Lauren’s classification
system have described two main histological types of gastric
cancer, intestinal and diffuse subtype, representing two entirely
different epidemiological and pathological entities. The intestinal-
type, characterized by cohesive neoplastic cells organized in gland-
like tubular structures, is more common in men and older people;
it usually arises following chronic infection by H. Pylori with
consequent chronic inflammation and atrophic gastritis [2,3]. On
the other hand, diffuse GC, histologically characterized by
infiltration and thickening of the stomach wall, occurs more
commonly in women and young patients; it is usually independent
from inflammation processes and can be hereditary, as a result of
germline mutation of E-cadherin [4]. The gastro-esophageal
junction (GEJ) cancer, arising from proximal stomach, is currently
considered as a third distinct entity. Despite the overall decrease in
GC incidence, the incidence of GEJ adenocarcinoma in Western
countries has increased over the last decades. Gastroesophageal
reflux disease and obesity are considered the major risk factors for
GEJ cancer and Barrett esophagus represents a precancerous
lesion for this type of tumour (Table 1).
This classification is also supported by clinical differences
between the GC subtypes. In particular, it is well known that
intestinal and diffuse GC have different metastatic pattern, with
diffuse type more likely to spread to the peritoneum compared to
intestinal GC. [5]. It has also been demonstrated that patients with
resected diffuse GC have a worse clinical outcome, when
compared stage-by-stage, to intestinal GC patients [6].
Recently, these epidemiological, pathological and clinical data
have been incorporated to define a new classification of GC that
identifies three tumour subtypes: type 1, proximal non-diffuse GC,
with the bulk of the tumour (.80%) located in the gastric cardia
and characterized by a non-diffuse pattern of infiltration; type 2,
diffuse GC, located anywhere in the stomach with an entirely
diffuse pattern of infiltration; type 3, distal non-diffuse GC, with
the bulk of the tumour located in the distal or mid stomach and a
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dominant pattern of intestinal type carcinoma [7]. Furthermore,
Shah et al have demonstrated that these GC subtypes, classified on
the basis of histology and anatomic location, have also distinct
gene expression profiles, supporting the hypothesis that GC
subtypes may be distinguished molecularly [8].
One of the clinical implications of this heterogeneity in GC
biology is the possible different sensitivity to chemotherapy
treatment among the different GC subtypes. Currently, the choice
of medical treatment for advanced GC does not take into account
the clinical and pathological heterogeneity of this disease.
Nevertheless, differences in response to treatment between
different subtypes have been reported by a subset analysis of the
FLAGS trial, which showed better overall for patients with diffuse
GC when treated with cisplatin/S-1 compared to cisplatin/5-FU
[9].
Aim of our analysis was to compare the clinical outcome, in
terms of response rate, RR, progression-free survival, PFS, and
overall survival, OS according to different GC subtypes (1,2,3) in




The study population was selected from a central database
including patients with gastric cancer treated and followed at our
institution. Clinical data were retrieved from medical charts.
Patients with histologically confirmed, inoperable locally ad-
vanced, recurrent or metastatic gastric or gastroesophageal
junction adenocarcinoma who have received a first-line combina-
tion chemotherapy with a two or three-drugs regimen were
included in our analysis. Patients were eligible if they had
measurable or non measurable disease; Eastern Cooperative
Oncology Group performance status 0–2; age $18; no central
nervous system metastasis. Patients with HER-2 positive gastric
cancer, including patients treated with trastuzumab, were exclud-
ed from our analysis.
The patients were divided in three subtypes as previously
described:
– type 1, proximal non-diffuse GC, with the bulk of the tumour
(.80%) located in the gastric cardia, with possible extension to
the distal part of the esophagus, and characterized by a non-
diffuse pattern of infiltration;
– type 2, diffuse GC, located anywhere in the stomach with an
entirely diffuse pattern of infiltration with no gland-forming,
intestinal type of carcinoma;
– type 3, distal non-diffuse GC, with the bulk of the tumour
located in the distal or mid part of the stomach and a dominant
pattern of intestinal type carcinoma, with or without
components of poorly differentiated carcinoma
Gastric cancer subtypes were determined retrospectively
reviewing the pathological report for each patient.
Ethics Statement
This study was approved by Ethical committee AOU Ospedali
Riuniti – Umberto I of our institution. All patients provided
informed written consent.
Treatment and Response evaluations
Chemotherapy regimens administered to patients included:
fluoropyrimidines and platinum based doublets, as cisplatin+5-
fluorouracil (5-FU), cisplatin+capecitabine, oxaliplatin+FU (FOL-
FOX) or capecitabine+oxaliplatin; 5-FU+irinotecan (FOLFIRI) or
5-FU+mytomicin C combinations; three drugs regimens including
anthracyclines (epirubicin, fluoropyrimidines and a platinum
derivate combinations as ECF, EOX, PELF), taxanes (docetaxel,
fluoropyrimidines and a platinum derivate combinations as TCF
or TOX) and mytomicin C (mytomicin C, fluoropyrimidines and
a platinum derivate combinations). Physical examination, com-
plete blood counts and biochemical tests were carried out before
each cycle of therapy. A chest and abdomen CT scan was
performed every three months and when disease progression was
clinically suspected by the treating physician to document the
extent of disease and to evaluate the response to treatment. The
response was assessed using the Response Evaluation Criteria in
Solid Tumours (RECIST) 1.0. After the end of treatment, patients
were followed every three months with laboratory and imaging
studies according to our internal guidelines. Disease status at last
follow-up and cause of death were determined by the medical
record and death certificates.
Statistical analysis
Patient, tumour, and treatment variables were compared
between the three subgroups using the chi-square for categorical
variables. For statistical analysis, overall survival (OS) and
Table 1. Gastric cancer subtypes features.
Gastric Cancer Subtype Prevalent Risk Factor
Proximal, Non-Diffuse GC (type 1) Environmental Tobacco use, Alcool
Clinical Obesity, High BMI, GERD
Genetic Non specifically identified
Diffuse GC (type 2) Environmental Non specifically identified
Clinical unknown
Genetic CDH1 mutation, Family history (non CDH1 mutant)
Distal, Non-Diffuse GC (type 3) Environmental High dietary salt, Tobacco, Age (peak 50–70 yrs), Low Fruit/vegetables intake
Clinical H.Pylori infection, Use of NSAIDs
Genetic Immune regulatory SNPs
Modified from Shah et al [8].
BMI: Body Mass Index, GERD: Gastroesphageal Reflux Disease, CDH1: Cadherin-1,
NSAIDs: Non-Steroideal Anti-Inflammatry Drugs, SNPs: Single Nucleotide Polymorphism.
doi:10.1371/journal.pone.0078544.t001
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progression-free survivial (PFS) were defined, respectively, as the
interval between the first day of first-line chemotherapy until the
time of the first occurrence of progression, death from any cause or
to the date of last follow-up visit and as the interval between the
first day of first-line chemotherapy to the date of death or to the
date of the last follow-up visit. Kaplan–Meier method was used to
estimate PFS and OS curves in the three subgroups; PFS and OS
were compared using the log-rank test and we used Cox-regression
models for survival multivariate analysis. Tested variables included
gender, ECOG PS (0–1 vs 2), stage (locally advanced vs metastatic
disease), first-line chemotherapy (three drugs vs two drugs
regimen), previous use of adjuvant or neoadjuvant treatment,
peritoneal carcinosis, number of metastatic sites (1 vs $2), use of
second line chemotherapy and disease subtype (1, 2 or 3) as
previous defined. We compared the overall response rates (ORR)
between the two groups, including complete response and partial
response, using the chi-square test.
Results
Characteristics of the patients
A total of 248 advanced gastric cancer patients treated with
chemotherapy between January 2003 and December 2011 were
included in our analysis. Patients characteristics are summarized in
Table 2. The majority of patients were males (65.3%); consistently
with epidemiological data the proportion of female patients was
found to be higher in group 2. The 11.3% of patients (28 patients)
presented with proximal non-diffuse GC and were classified as
type 1; 112 patients (45.2%) had a diagnose of diffuse GC and
were classified as type 2, while type 3 GC, distal-non diffuse GC,
included 108 patients (43.5%).
The 3 groups of patients resulted comparable for most of
baseline characteristics of clinical relevance (age, ECOG PS, stage,
number of metastatic sites). Most of the patients (91.9%) had
metastatic disease while the remaining 8.1% presented with locally
advanced, unresectable disease. More than a half of patients
(58.1%) had undergone previous surgery for their disease and
20.9% of the patients also received neoadjuvant or adjuvant
chemotherapy. As expected, type 2 GC patients, presenting diffuse
histology, had a higher incidence of peritoneal carcinosis
compared to other groups (50% vs 29.6% in type 3 and 28.6%
in type 1).
Treatment
One-hundred and forty-seven patients (59.3%) received a two
drugs fluoropyrimidine-based chemotherapy regimen as first-line
treatment. Most of the patients received a combination including a
platinum derivate and a fluoropyrimidine (100 patients); the
remaining 47 patients received a fluoropyrimidine and irinotecan
(22 patients) or mytomicin C (25 patients).
One-hundred and one patients (40.7%) received a three drugs
regimen as first-line combination chemotherapy, including a
platinum derivate, a fluoropyrimidine and a third drug; in
particular, 35 patients received an anthracyclines based combina-
tion, 27 patients received a taxanes based regimen while 39
patients received a triplet containing mytomicin. No significant
difference was found between the three groups of patients in the
use of three or two drugs regimen (p= 0.18). First-line regimens
administered in the two groups of patients are summarized in
Table 3. A total of 137 patients (55.2%) received a second line
chemotherapy, with no significant differences between the three
GC subtypes. FOLFIRI (5-fluorouracil, leucovorin and irinotecan)
was the most commonly used regimen in this setting. Other second
line treatments included taxanes (paclitaxel or docetaxel) and
FOLFOX (5-fluorouracil, leucovorin and oxaliplatin).
Efficacy
In 223 patients with measurable disease, the overall response
rate to first-line chemotherapy in patients was 29.6%. We
observed significant differences in response rate according to
Table 2. Patients’ Characteristics.
Type 1 Type 2 Type 3
(28 pts) (112 pts) (108 pts)
Age Median (Range),ys 63 (51–76) 61 (29–85) 66 (39–81)
Gender M 24 60 78 p= 0.0008
F 4 52 30
ECOG PS 0–1 24 78 84 p= 0.14
2 4 34 24
Surgery Yes 14 60 70 p= 0.16
No 14 52 38
Prior Neoadjuvant/Adjuvant Chemotherapy Yes 2 28 22 p= 0.11
No 26 84 86
Stage Locally advanced 2 10 4 p= 0.28
Metastatic 26 102 104
Metastatic Sites 1 12 54 62 p= 0.55
$2 14 48 42
Peritoneal Carcinosis Yes 8 56 32 p= 0.004
No 20 56 76
Second Line Chemotherapy Yes 18 60 59 p= 0.59
No 10 52 49
doi:10.1371/journal.pone.0078544.t002
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disease subtype: the higher response rate was reported in subtype 1
(12/26 patients, 46.1%), while response rate was 34.3% in subtype
3 patients and 20.4% in patients with type 2 gastric cancer
(p = 0.015), as described in Table 4. Subtype 2 gastric cancer
patients presented a shorter PFS compared to other subgroups
with a median PFS of 4.2 months compared to a median PFS of
7.2 months for type 1 patients and 5.9 months for type 3
(p = 0.011) (Figure 1). These differences translated in statistically
significant differences in OS. In particular, median OS was 9.8
months in subtype 2 patients compared to a median OS of 11.5
months in subtype 1 and 11.0 months in subtype 3 patients
(p = 0.022) (Figure 2). At survival multivariate analysis, when we
considered together the two disease subtypes with better outcome
(type 1 and type 3), type 2 gastric cancer subtype was found to be
an independent predictor for OS (HR=1.41; 95% CI 1.02–1.94,
p = 0.038) together with previous surgery (HR=0.55; 95% CI
0.39–0.79, p = 0.0012), use of adjuvant or neoadjuvant treatment
(HR=0.57; 95% CI 0.35–0.90, p= 0.018) and use of second line
chemotherapy (HR=0.53; 95% 0.39–0.73, p = 0.0001).
Discussion
Advanced gastric cancer is an aggressive disease with high
mortality rate. Combinations chemotherapy is the treatment of
choice for advanced GC but despite recent progress in cancer
treatment, patients’ prognosis remains dismal. Currently, even if
GC heterogeneity is well recognized, medical management of
gastric cancer is not influenced by epidemiological, histological or
anatomical considerations. Our analysis has shown how clinical
outcome of advanced GC patients treated with chemotherapy is
different in terms of RR, PFS and OS according to histology and
tumour location, with proximal non-diffuse GC presenting the
more favourable outcome.
Clinical implications of GC biological heterogeneity are
increasingly being identified in recent trials. In a subset analysis
of a phase II trial evaluating bevacizumab with a modified DCF
regimen (docetaxel, cisplatin, 5-fluorouracil) in advanced GC
patients [10] diffuse GC was shown to have significantly worse
PFS and OS compared to other subtypes.
Diffuse tumours also presented the worse response rate with
38% compared to 56% of distal/body diffuse GC and 85% of
proximal non-diffuse GC. Interestingly, in this trial gastroesoph-
ageal tumours, usually considered more aggressive and presenting
a worse prognosis compared to tumours arising from the rest of the
stomach [11,12] had a greater benefit from the treatment. Authors
suggested that bevacizumab may be more active in this subset,
proximal non-diffuse GC, and may improve the clinical outcome
of patients overcoming the adverse prognosis characteristics.
Along with these data, our analysis has shown an adverse
prognosis for type 2 advanced GC patients treated with
combination chemotherapy. Nevertheless, type 1 (proximal non-
diffuse) GC patients in our study presented a lower response rate,
about 46%, compared to that observed in the phase II trial by
Shah et al. A possible explanation is that a more than a half of
patients (59.3%) in our study did not receive a three-drugs
chemotherapy regimen but a two drug combination and none of
the patients received bevacizumab. Suggestions of variable efficacy
of treatment on the basis of disease subtype in GC have been
observed also in large phase III trial, such as the already cited
FLAGS or the ToGA trial. The ToGA trial was an international
phase III trial that randomized HER2 positive advanced GC
patients to cisplatin and capecitabine/fluorouracil plus trastuzu-
mab or to chemotherapy alone [13]. HER2 expression is more
common in intestinal type tumours than in other subtypes [14]
and indeed diffuse GC represented only 9% of all patients enrolled
in the trial. A subset analysis showed that the addition of
trastuzumab to chemotherapy in this subgroup of patients had no
effect on survival with a HR for OS of 1.07 (0.56–2.05) versus a
HR of 0.69 (0.54–0.88) for intestinal type GC patients.
Evidences of different response to treatment between GC
subtypes have been reported not only in patients with advanced
disease but also in the adjuvant setting. In particular, in a recent
update of INT-0116 study, evaluating post-operative chemo-
radiotherapy in patients with resected GC, it has been shown that
the benefit of adjuvant treatment is minimal in patients with
diffuse histology while is significant in all the other subsets [15].
Similar findings have been observed also in the ITACA-S trial, a
multicenter phase III trial comparing 5-fluorouracil and leucov-
orin versus a sequential regimen including irinotecan and 5-
fluorouracil followed by cisplatin and docetaxel in the adjuvant
treatment of resected GC patients. In a subgroups analysis of the
Table 3. First-line chemotherapy regimens administered in
the three groups of patients.
Type 1 Type 2 Type 3
n. pts (%) n. pts (%) n. pts (%)
Two drugs regimens 16 (57.1%) 60 (53.6%) 71 (65.7%)
Fluoropyrimidine+platinum derivate 12 40 48
Fluoropyrimidine+irinotecan 4 8 10
Fluoropyrimidine+mytomicin C 0 12 13




Taxanes-containing chemotherapy 3 14 10
Mytomicin-containing chemotherapy 5 20 14
doi:10.1371/journal.pone.0078544.t003
Figure 1. Progression-free survival according to subtypes.
________ type 1 proximal non diffuse GC (median PFS= 7.2 months).
------------ type 2 diffuse GC (median PFS= 4.2 months). ?????????????type
3 distal non diffuse GC (median PFS= 5.9 months). P = 0.011.
doi:10.1371/journal.pone.0078544.g001
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trial, which could not demonstrate any benefit for the intensive
treatment versus the fluorouracil monotherapy, the authors
compared the outcome of patients according to disease subtype,
dividing the patients in type 1, type 2 and type 3 as defined by
Shah et al. The subtype 2, diffuse GC, presented a worse outcome
in terms of OS compared to type 3 (HR=1.35; 95% CI 1.06–
1.72, p = 0.016) while no significant difference in terms of
prognosis was found between subtype 1 and 3. None of the three
subtypes showed a benefit for the experimental arm versus the 5-
fluorouracil arm [16].
Although we think that our results are interesting and relevant,
we acknowledge that a few points should be more accurately
discussed. Firstly, our analysis excluded HER-2 positive GC
patients. Even if we believe that also HER-2 positive GC requires
a classification, we decided to exclude these patients from our
study considering the different biology of this disease, the potential
prognostic role of HER-2 expression and the possible confounding
factor represented by trastuzumab treatment. The use of different
chemotherapy regimens in the study population may affect the
results, however we found no difference in the use of two or three
drugs regimens between the three subtypes of patients. Moreover,
the number of patients in some subgroups, in particular subtype 1
patients, is low and the difference observed in OS, although
statistically significant, is actually small and of questionable
clinical value. Nevertheless, in our study this difference in OS
is associated with a relevant difference in response rate and
PFS between the three subgroups of patients. Our analysis
suggests that different GC subtypes may present different
sensitivity to chemotherapy treatment. Future clinical trials,
evaluating chemotherapy treatment in advanced GC patients,
should take in account these differences for a better stratifica-
tion of patients. Indeed, one of the possible explanation for the
negative results of recent phase III trials evaluating new
cytotoxic or target therapies, such as FLAGS or AVAGAST
[17] is that GC is a heterogeneous disease with different
biology that may affect response to treatment. Actually,
preliminary evidences have shown that the three distinct GC
subtypes identified on histopathologic and anatomic criteria,
present different gene expression profiles [7]. In the last few
years, several studies have demonstrated that molecular
markers may correlate to either response or toxicity to specific
antineoplastic drugs in GC [18]. Differential expression of
biological factors involved in chemotherapy activity, including
targets of chemotherapeutic agents, such as thymidylate
synthase (TS) for 5-FU, but also genes involved in drug
metabolism, may explain the different response to treatment
observed in our study. For example, a study by Kamoshida S
et al assessed expression of TS, DPD (dihydropyrimidine
dehydrogenase) and TP (thymidine phosphorylase) levels in
different tumour types, including intestinal-type and diffuse-
type gastric adenocarcinoma. The authors found high level of
expression of TS, which may be associated with poor response
to 5-FU based chemotherapy, in diffuse GC while TS was not
overexpressed in intestinal type GC [19].
In conclusions, our study suggests that response to chemother-
apy may be different in advanced GC patients, according to
tumour histology and anatomic location. Genetic and translational
studies are warranted to improve the understanding of molecular
drivers and pathways of different GC subtype that may help to
identify prognostic and predictive biomarkers as well as to identify
specific targets for therapy.
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